Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma

Cohort Study of Patients With Primary Hepatocellular Carcinoma or Cholangiocarcinoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04340986

Acronym

CHC/CC

Enrollment

1250

Registered

2020-04-10

Start date

2020-09-02

Completion date

2030-09-30

Last updated

2024-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholangiocarcinoma, Hepatocellular Carcinoma

Keywords

hepatocellular carcinoma, cholangiocarcinoma, cohort

Brief summary

The main objective is to describe the evolution of patients treated for a primary malignant hepatobiliary tumor (hepatocellular carcinoma or cholangiocarcinoma) over the long course.

Detailed description

The collection of data from patients with CHC and cholangiocarcinomas who are cancers with poor prognosis is a major challenge to improve patients'care (diagnosis, prognosis); facilitate the search for new therapeutic targets and the follow-up of clinical studies; and develop personalized treatments.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

Inclusion Criteria : * Age ≥ 18 years olds * Medical care in Nephrology department since 2015 Cholangiocarcinoma: \- Histologically and cytologically documented cholangiocarcinoma, regardless of the stage of the disease Hepatocellular carcinoma: * Hepatocellular carcinoma at any stage of the disease, presenting the diagnostic criteria according to the diagnostic criteria of Barcelona : Tumor of more than 1 cm, developed on cirrhosis liver with arterial phase hyperenhancement and washout in the portal venous or delayed phases on CT and MRI * Hepatocellular histologically documented

Exclusion criteria

\- Lack of patient non-opposition

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	5 years	Hepatocellular carcinoma and Cholangiocarcinoma : Overall survival is defined as the survival 5 years after the inclusion.

Secondary

Measure	Time frame	Description
Overall survival	5 years	Hepatocellular carcinoma :Overall survival is defined as the survival after 5 years of inclusion.
Disease free survival	2 and 5 years	Cholangiocarcinoma : 2 and 5 years after surgical resection
Progression time under chemotherapy	Time of progression under chemotherapy up to 5 years	Cholangiocarcinoma : Time of progression under chemotherapy is defined by the delay between the start of chemotherapy and tumor progression (appearance of a new lesion or increase in size of more than 30%)

Countries

France

Contacts

Primary ContactMarie LEQUOY, MD

marie.lequoy@aphp.fr+330149283154

Outcome results